LHRH-agonist treatment in metastatic prostate carcinoma
- 15 April 1984
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 20 (4), 483-493
- https://doi.org/10.1016/0277-5379(84)90233-5
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist.BMJ, 1983
- Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.BMJ, 1983
- The presence of LHRH‐like receptors in Dunning R3327H prostate tumorsFEBS Letters, 1983
- SUSTAINED SUPPRESSION OF TESTOSTERONE PRODUCTION BY THE LUTEINISING-HORMONE RELEASING-HORMONE AGONIST BUSERELIN IN PATIENTS WITH ADVANCED PROSTATE CARCINOMAThe Lancet, 1982
- TREATMENT WITH A LUTEINISING-HORMONE-RELEASING-HORMONE ANALOGUE (BUSERELIN) IN PREMENOPAUSAL PATIENTS WITH METASTATIC BREAST CANCERThe Lancet, 1982
- Effect of chronic administration of a highly potent LHRH agonist on prostate size and secretory function in geriatric dogsThe Prostate, 1982
- Sertoli–Leydig cell communication via an LHRH-like factorNature, 1981
- Inhibition of the action of sex steroids by gonadotropin-releasing hormone (GnRH) agonists: A new biological effectLife Sciences, 1981
- Reduction of LH-RH pituitary and estradiol uterine binding sites by a superactive analog of luteinizing hormone-releasing hormoneBiochemical and Biophysical Research Communications, 1980
- THE IMPORTANCE OF PITUITARY TUMOUR SIZE IN PATIENTS WITH HYPERPROLACTINAEMIA IN RELATION TO HORMONAL VARIABLES AND EXTRASELLAR EXTENSION OF TUMOURClinical Endocrinology, 1980